WO2012148140A3 - 혈관 신생 억제 및 항산화 효과를 가지는 이미다졸계 알칼로이드 유도체 및 이의 제조방법 - Google Patents

혈관 신생 억제 및 항산화 효과를 가지는 이미다졸계 알칼로이드 유도체 및 이의 제조방법 Download PDF

Info

Publication number
WO2012148140A3
WO2012148140A3 PCT/KR2012/003103 KR2012003103W WO2012148140A3 WO 2012148140 A3 WO2012148140 A3 WO 2012148140A3 KR 2012003103 W KR2012003103 W KR 2012003103W WO 2012148140 A3 WO2012148140 A3 WO 2012148140A3
Authority
WO
WIPO (PCT)
Prior art keywords
imidazole
antioxidant effects
production method
angiogenesis inhibition
alkaloid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/003103
Other languages
English (en)
French (fr)
Other versions
WO2012148140A2 (ko
Inventor
송호영
김성진
박수호
이향숙
박태교
우성호
김용주
김태윤
김병학
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Clue and Solution Co Ltd
Ligachem Biosciences Inc
Original Assignee
Bio Clue and Solution Co Ltd
Legochem Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Clue and Solution Co Ltd, Legochem Biosciences Inc filed Critical Bio Clue and Solution Co Ltd
Publication of WO2012148140A2 publication Critical patent/WO2012148140A2/ko
Publication of WO2012148140A3 publication Critical patent/WO2012148140A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 명세서 상의 화학식 1로 표시되는 이미다졸계 알칼로이드 유도체, 그것의 약제학적으로 허용되는 염, 수화물, 용매화물, 이성질체 또는 프로드럭과, 이의 제조방법 및 이를 함유하는 혈관 신생 억제 및 항산화 효과를 가지는 의약 조성물에 관한 것이다. 상기 화학식에서, L, M, m, X, Y, R1 및 R2는 명세서에서 정의한 바와 같다.
PCT/KR2012/003103 2011-04-29 2012-04-23 혈관 신생 억제 및 항산화 효과를 가지는 이미다졸계 알칼로이드 유도체 및 이의 제조방법 Ceased WO2012148140A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110041031A KR20120122705A (ko) 2011-04-29 2011-04-29 혈관 신생 억제 및 항산화 효과를 가지는 이미다졸계 알칼로이드 유도체 및 이의 제조방법
KR10-2011-0041031 2011-04-29

Publications (2)

Publication Number Publication Date
WO2012148140A2 WO2012148140A2 (ko) 2012-11-01
WO2012148140A3 true WO2012148140A3 (ko) 2013-01-03

Family

ID=47072878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/003103 Ceased WO2012148140A2 (ko) 2011-04-29 2012-04-23 혈관 신생 억제 및 항산화 효과를 가지는 이미다졸계 알칼로이드 유도체 및 이의 제조방법

Country Status (2)

Country Link
KR (1) KR20120122705A (ko)
WO (1) WO2012148140A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168081B2 (en) 2017-07-25 2021-11-09 Seoul National University R&Db Foundation Alkaloid derivative having angiogenesis inhibitory effect, and pharmaceutical composition containing same
CN108623524B (zh) * 2018-04-17 2021-02-26 安徽农业大学 咪唑二聚体生物碱及其制备方法和应用
SG11202101486RA (en) 2018-08-16 2021-03-30 Innate Tumor Immunity Inc Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
KR102823891B1 (ko) 2020-01-14 2025-06-20 서울대학교산학협력단 혈관생성 저해 효과를 가지는 n-페닐벤조티아졸-2-아민 화합물 및 그를 포함하는 약제학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100404580B1 (ko) * 2000-04-20 2003-11-05 한국해양연구원 원도닌 ａ 및 그의 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100404580B1 (ko) * 2000-04-20 2003-11-05 한국해양연구원 원도닌 ａ 및 그의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHANG, Y. H. ET AL.: "Dihydroxystyrene Metabolites from an Association of the Sponges Poecillastra wondoensis and Jaspis sp", J. NAT. PROD., vol. 71, no. 5, 12 April 2008 (2008-04-12), pages 779 - 783 *

Also Published As

Publication number Publication date
WO2012148140A2 (ko) 2012-11-01
KR20120122705A (ko) 2012-11-07

Similar Documents

Publication Publication Date Title
WO2013022236A3 (ko) 신규 벤조산아미드 화합물
EP4643945A8 (en) Neuroactive steroids and methods of use thereof
EP4582424A3 (en) 1,2-naphthoquinone derivative and method for preparing same
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
WO2014197345A3 (en) Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
MY187718A (en) Pharmaceutical formulations
PH12013501800A1 (en) Tricyclic gyrase inhibitors
MX361653B (es) Procedimiento para la preparación de derivados del ácido biliar.
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
MX348654B (es) Composicion farmaceutica con biodisponibilidad mejorada para compuesto hidrofobico de alto punto de fusion.
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
PH12015500211A1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2012085927A3 (en) Tadalafil compositions
WO2013121235A3 (en) Process for preparation of dronedarone by removal of hydroxyl group
IN2012DN04868A (ko)
WO2013062966A3 (en) Methanol derivatives as trpv3 modulators
MX2009008249A (es) Composicion farmaceutica que comprende derivado de camptotecina.
WO2012118309A3 (ko) 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
PH12015501146A1 (en) Hydantoin derivative
WO2015044853A3 (en) Process for preparation of dimethyl fumarate
WO2013111162A3 (en) Process for preparation of fingolimod
WO2012155226A8 (pt) Processo para a produção de derivados de pyrostegia venusta, derivados de pyrostegia venusta, composições farmacêuticas e seus usos
WO2012014052A3 (en) Novel coated extended release pharmaceutical compositions containing paliperidone
PH12013500210A1 (en) Highly crystalline valsartan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12777004

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 21/03/2014)

122 Ep: pct application non-entry in european phase

Ref document number: 12777004

Country of ref document: EP

Kind code of ref document: A2